Corrects EPS in Key Details table to -$0.41 from $0.41

Overview

• U.S. biopharmaceutical firm's Q1 revenue rose 17% on higher Ameluz sales and price increases

• Adjusted EBITDA loss narrowed year over year, reflecting improved gross margins under new earnout structure

Outlook

• Company remains focused on achieving sustained profitability and cash-flow breakeven

Result Drivers

• AMELUZ SALES AND PRICING - Revenue growth was primarily driven by a 16% increase in Ameluz units sold and a price increase implemented in Q4 2025

• GROSS MARGIN EXPANSION - Gross margin rose to 80% from 62% due to the new earnout structure after the strategic transaction with Biofrontera AG

• HIGHER OPERATING EXPENSES - Operating expenses rose due to increased selling and marketing costs, lower sales team turnover, increased legal expenses, and manufacturing costs from the strategic transaction

Company press release: ID:nGNXbvxJNl

Key Details

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.